{preheader}
  ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌   ‌
 
Click here to see this online
 
 
 

April 25, 2019

 
NEWS
 
 
 

Cancer Center at Illinois Welcomes New Associate Director for Administration
The CCIL is pleased to announce Barry Schatz as the Associate Director for Administration for the Cancer Center at Illinois. Barry comes to Illinois from Loyola University where he was the Associate Director for Administration at Cardinal Bernardin Cancer Center. Schatz holds an MS in Health Systems Administration from the University of Michigan and a BS in Hospital Administration/Psychology from the University of Illinois. In addition to his administrative abilities, Barry is a cancer survivor since June 2000, giving him insight into the patient perspective of treatment. 

 
 
 
 
 

Cancer Study: Drugs Reprogram Genes in Breast Tumors to Prevent Endocrine Resistance
A new Illinois study led by Zeynep Madak-Erdogan finds that treating breast tumors with two cancer drugs simultaneously may prevent endocrine resistance by attacking the disease along two separate gene pathways. This novel two-drug protocol can reverse endocrine resistance in estrogen receptor-positive breast tumors, causing the tumor cells to self-destruct. Read more.

 
UPCOMING EVENTS

TiMe Day Symposium
The third annual TiMe Day Symposium is tomorrow! The symposium will highlight research from the program, include keynote and plenary talks, and culminate with a poster session for graduate and undergraduate students. Find out more

 
 
 
 

REGISTER NOW: Cancer Research Advocacy Day
Registration is now open for Cancer Research Advocacy Day. The event is a way to promote interactions between cancer survivors, researchers, and clinicians and honor those who have been impacted by the disease. Find out more.

 
 
CALL FOR POSTER ABSTRACTS

Individualizing Medicine Conference
Submissions are encouraged on topics related to precision oncology, including but not limited to: immunotherapy, genomics, precision therapy, pharmacogenomics, bioinformatics, biomarker discovery, and others. Clinicians, physician researchers, students and others interested in precision oncology are invited to submit an abstract. The deadline is June 17. Learn more.

EXTERNAL FUNDING OPPORTUNITIES

Alex's Lemonade Stand Foundation—"A" Awards
Alex's Lemonade Stand Foundation 
Deadline: May 20, 2019

**New** Integrated Approach to Breast Health Equity
Pfizer
Deadline: June 17, 2019

Leukemia Research Grants
When Everyone Survives Foundation
Deadline: June 1, 2019 

Ovarian Cancer: (1) Investigator-Initiated Research Award; (2) Pilot Award
DOD
Deadline: July 24, 2019

Ovarian Cancer: (1) Clinical Development Award; (2) Dean and Assistant Dean (Leadership) Award; (3) Early Career Investigator Award
DOD
Deadline: July 31, 2019

Lung Cancer Research: (1) Career Development Award; (2) Idea Development Award; (3) Investigator-Initiated Translational Research Award; (4) Translational Research Partnership Award
DOD
Deadline: August 21, 2019

Peer Reviewed Cancer Research: (1) Career Development Award; (2) Horizon Award; (3) Idea Award with Special Focus; (4) Impact Award; (5) Translational Team Science Award
DOD
Deadline: September 21, 2019

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (No R33 Clinical Trials)
National Institutes of Health
Deadline: September 27, 2019

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (No R33 Clinical Trials)
National Institutes of Health
Deadline: September 27, 2019

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (No R21 Clinical Trials)
National Institutes of Health
Deadline: September 27, 2019

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (No R21 Clinical Trials)
National Institutes of Health
Deadline: September 27, 2019

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
National Institutes of Health
Deadline: September 27, 2019 

Revisions for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
National Institutes of Health
Deadline: September 27, 2019 

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)
National Institutes of Health
Deadline: September 27, 2019
 

 

If you received an award, published a paper, or have news to share, we want to hear from you.
Send your news items to cancercenter@illinois.edu

Visit the Cancer Center Events Calendar
for upcoming cancer-related activities and events.

Follow us on Twitter at @CancerCenterIL.


cancer.illinois.edu | cancercenter@illinois.edu | @CancerCenterIL